GATTACCECA , Florence

CAR-T cells are a living drug, able to proliferate in the organism.Dose-exposure relationship is highly variable.Exposure to CAR-T cells is correlated to the clinical response.To understand the dose-exposure relationship, technical challenges need to be taken up in order to quantify CAR-T cells in blood and tissues of interest.

Background: Cefotaxime is a beta-lactam antibiotics commonly used in intensive care unit (ICU). In this population, pathophysiological modifications induce a high inter-individual and intra-individual pharmacokinetic variability. This variability can result in supra or sub-therapeutic concentrations of cefotaxime and adapted drug regimen are...

Background and objectivesCritically ill patients display pathophysiological features that cause high inter- and intra-individual pharmacokinetic (PK) variability, which can result in supra or sub-therapeutic drug concentrations. Among the factors involved in PK variability, renal clearance appears as an important contributor, whether as renal...

Background :Cefotaxime is a beta-lactam antibiotics commonly used in intensive care unit (ICU) patients. In this population, pathophysiological modifications induce a high inter- and intra-individual pharmacokinetic variability which can result in supra or sub-therapeutic concentrations of cefotaxime. Indeed, it has recently been shown that the...

International audience

International audience

International audience

All the abstracts for the past PAGE meetings can be accessed online through either the search function on the left or by going to the relevant PAGE meetinghttps://www.page-meeting.org/default.asp?keuze=search

Background and Objectives: Nanoparticles (NPs) have been developed for over two decades in order to improve the pharmacokinetic (PK) profile of drugs and to target specific tissues. The diversity of NPs in terms of structures and properties results in specific PK behaviors. Physiologically-based pharmacokinetic (PBPK) modeling is a powerful...

PurposeThe aim of the present study was to characterize the pharmacokinetics of irinotecan and its four main metabolites (SN-38, SN-38G, APC and NPC) in metastatic colorectal cancer patients treated with FOLFIRI and FOLFIRINOX regimens and to quantify and explain the inter-individual pharmacokinetic variability in this context.MethodsA...